Insmed (INSM) Upgraded to Hold at BidaskClub


Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Insmed from a "hold" rating to a "buy" rating and set a $32.00 price objective on the stock in a research note on Thursday, January 25th.



from Biotech News